Olanzapine: A review of its use in the treatment of bipolar I disorder

CNS Drugs

Volumn 15, Issue 11, 2001, Pages 871-904

  Bhana, N ^a   Perry, C M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Bipolar disorder; Olanzapine; Pharmacodynamics; Pharmacokinetics; Therapeutic use

Indexed keywords

CARBAMAZEPINE; CIPROFLOXACIN; CYTOCHROME P450 1A1; CYTOCHROME P450 2D6; DOPAMINE 2 RECEPTOR; FLUVOXAMINE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; NEUROTRANSMITTER RECEPTOR; OLANZAPINE; SEROTONIN 2A RECEPTOR; VALPROATE SEMISODIUM;

BEHAVIOR; CLINICAL TRIAL; COGNITION; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG OVERDOSE; DRUG TOLERABILITY; HUMAN; LACTATION; MANIC DEPRESSIVE PSYCHOSIS; NEUROLEPTIC MALIGNANT SYNDROME; PHARMACODYNAMICS; PREGNANCY; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; QUALITY OF LIFE; REVIEW; SMOKING; SOMNOLENCE; TARDIVE DYSKINESIA; VERTIGO; WEIGHT GAIN; XEROSTOMIA;

EID: 0035212353     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200115110-00005     Document Type: Review

References (149)

1. Mood disorders
2. Management of acute mania
3. A medication algorithm for treatment of bipolar rapid cycling
4. Bipolar disorder
5. Emerging options in the treatment of bipolar disorders
6. Olanzapine: A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses
7. Olanzapine: An updated review of its use in the management of schizophrenia
8. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania
9. Olanzapine: Pharmacokinetic and pharmacodynamic profile
10. Bipolar disorders: Leads from the molecular and cellular mechanisms of action of mood stabilisers
11. Olanzapine: A basic science update
12. Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium
13. Receptor pharmacology of neuroleptics: Relation to clinical effects
14. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia
15. 2 receptor occupancy of olanzapine in schizophrenia: A PET investigation
16. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons
17. In vitro and in vivo biochemistry of olanzapine: A novel, atypical antipsychotic drug
18. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum
19. The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent
20. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice
21. Reversal of isolation rearing-induced deficits in prepulse inhibition by Seroquel and olanzapine
22. Antipsychotic agents antagonize the non-competitive N-methyl-D-aspartate antagonist-induced behaviors
23. Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test
24. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine
25. Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule
26. Olanzapine, an atypical antipsychotic, increases rates of punished responding in pigeons
27. Olanzapine moderately increases conflict responding but does not produce a benzodiazepine-like cue in rat
28. Effect of olanzapine on behavioural changes induced by FG 7142 and dizocilpine on active avoidance on plus maze tasks
29. A comparison of the effects of olanzapine, haloperidol and placebo on cognitive and psychomotor functions in healthy elderly volunteers
30. 2C receptors in vivo
31. Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis
32. Olanzapine versus placebo in the treatment of acute mania
33. Efficacy of olanzapine in acute bipolar mania: A double-blind, placebo-controlled study
34. New onset diabetes and atypical antipsychotics
35. Atypical antipsychotics: Impaired glucose metabolism
36. Olanzapine versus divalproex for the treatment of acute mania
37. Divalproex sodium vs. olanzapine for the treatment of mania in bipolar disorder
38. Olanzapine versus haloperidol treatment of acute mania
39. Antipsychotic agents and bipolar disorder
40. Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients
41. 2 receptor occupancy in olanzapine-treated patients
42. 2 receptor binding after long-term treatment with antipsychotics in humans: A clinical PET study
43. Psychopharmacology of olanzapine: A review
44. Effects of olanzapine on regional C-Fos expression in rat forebrain
45. Olanzapine-induced Fos expression in the rat forebrain; cross-tolerance with haloperidol and clozapine
46. Mechanisms of action of atypical antipsychotic drugs: A critical analysis
47. 1-adrenergic receptors in vitro
48. Behavioral pharmacology of olanzapine: A novel antipsychotic drug
49. Antipsychotic medications and the elderly: Effects on cognition and implications for use
50. Olanzapine: Interaction study with imipramine
51. Sudden unexplained death in psychiatric in-patients
52. Association of autonomic dysfunction and clozapine
53. Some adverse effects of antipsychotics: Prevention and treatment
54. Effects of newer atypical antipsychotics on autonomic neurocardiac function: A comparison between amisulpride, olanzapine, sertindole, and clozapine
55. The effects of olanzapine, risperidone, and haloperidol on plasma levels in patients with schizophrenia
56. Bodyweight gain induced by psychotropic drugs: A few agents are the main culprits
57. Atypical antipsychotics and weight gain - A systematic review
58. Disposition and biotransformation of the antipsychotic agent olanzapine in humans
59. Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia
60. Biotransformation of post-clozapine antipsychotics: Pharmacological implications
61. The synthesis and biological activity of some known and putative metabolites of the atypical antipsychotic agent olanzapine (LY170053)
62. Combined population pharmacokinetic analysis of olanzapine in healthy volunteers
63. Pharmacokinetics (PK) and pharmacodynamic (PD) interactions between fluvoxamine and olanzapine
64. Suspected ciprofloxacin inhibition of olanzapine resulting in increased plasma concentration
65. Olanzapine serum concentrations in psychiatric patients given standard doses: The influence of comedication
66. A pharmacokinetic interaction between carbamazepine and olanzapine: Observations on possible mechanism
67. Pharmacokinetics of olanzapine in Caucasian, Chinese, and Japanese subjects
68. Disposition of olanzapine in Chinese schizophrenic patients
69. Olanzapine transfer by human placenta
70. Healthy outcome under olanzapine treatment in a pregnant woman
71. Presence of olanzapine in breast milk
72. Interaction between olanzapine and lithium in healthy male volunteers
73. Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men
74. Interaction between olanzapine and haloperidol
75. Olanzapine serum concentrations lowered by concomitant treatment with carbamazepine
76. Olanzapine compared to lithium in mania: A double-blind randomized controlled trial
77. Long-term olanzapine therapy in the treatment of bipolar I disorder: An open-label continuation phase study
78. Placebo effect in randomized, controlled studies of acute bipolar mania and depression
79. A rating scale for mania: Reliability, validity and sensitivity
80. Development of a rating scale for primary depressive illness
81. Modification of the Clinical Global Impression (CGI) scale for use in bipolar illness (BP): The CGI-BP
82. The Brief Psychiatric Rating Scale
83. Depression during mania: Treatment response to olanzapine or placebo
84. Olanzapine versus placebo: Antimanic effect and cognitive function in psychotic and nonpsychotic bipolar
85. Olanzapine versus haloperidol: A prospective comparison of clinical and humanistic outcomes in bipolar disorder
86. Atypical antipsychotics in bipolar and schizoaffective disorders
87. A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder
88. Olanzapine in treatment-resistant bipolar disorder
89. Olanzapine therapy in treatment-resistant psychotic mood disorders: A long-term follow-up study
90. Olanzapine in the treatment of rapid-cycling bipolar I patients
91. A comparison of atypical antipsychotic agents as an adjunct to mood stabilizers in rapid-cycling bipolar disorder
92. Is olanzapine a mood stabilizer?
93. Atypical antipsychotics as enhancement therapy in rapid cycling mood states: A case study
94. Practice parameters for the assessment and treatment of children and adolescents with bipolar disorder
95. Bipolar disorder in children and adolescents: A guide to diagnosis and treatment
96. Pediatric mania: A developmental subtype of bipolar disorder?
97. A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder
98. Olanzapine in the treatment of adolescent acute mania: A report of seven cases
99. Mood stabilizer augmentation with olanzapine in acutely manic children
100. Treatment of bipolar I disorder in an adolescent with olanzapine
101. Open-label olanzapine treatment in five preadolescent children
102. Clinical predictors of acute response with olanzapine in psychotic mood disorders
103. The role of olanzapine in dysphoric mania
104. Adjunctive use of olanzapine in mood disorders: Five case reports
105. Effective treatment of mania with olanzapine: 2 case reports
106. Treatment of bipolar mixed state with olanzapine
107. Rapid efficacy of olanzapine augmentation in nonpsychotic bipolar mixed states
108. Efficacy of olanzapine combined with valproate or lithium in the treatment of bipolar disorder
109. The pharmacovigilance of olanzapine - Results of a post-marketing surveillance study on 8858 patients in England
110. Hypothermia in 2 patients treated with atypical antipsychotic medication
111. Olanzapine-induced urinary incontinence: Treatment with ephedrine
112. Olanzapine: Weight gain and therapeutic efficacy
113. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia
114. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia
115. Tardive dyskinesia in affective disorders
116. Improvement of tardive dyskinesia in a bipolar patient with olanzapine
117. Possible induction of mania and hypomania by olanzapine or risperidone: A critical review of reported cases
118. Olanzapine-induced psychotic mania in bipolar schizoaffective disorder
119. Olanzapine is not associated with exacerbation of bipolar mania
120. Neuroleptic malignant syndrome associated with olanzapine
121. The course and management of bipolar disorder during pregnancy
122. Psychotropic drug use during pregnancy: Weighing the risks
123. Antipsychotics during pregnancy
124. Olanzapine-exposed pregnancies and lactation: Early experience
125. Estimated costs of treatment for bipolar affective disorder in a large employer database
126. The lifetime cost of bipolar disorder in the US; an estimate for new cases in 1998
127. Cost savings associated with treating bipolar patients with olanzapine
128. Clinical, humanistic and economic outcomes associated with long-term olanzapine treatment of mania
129. Changes in health-related quality of life of patients with bipolar disorder treated with olanzapine
130. Impact of olanzapine added to lithium or valproate on the quality of life of patients with bipolar disorder
131. Olanzapine
132. Assessment and treatment of bipolar disorder in the elderly
133. Treatment advances in bipolar disorder - Making up for lost time
134. Long term treatment of bipolar disorder
135. Is lithium still the maintenance treatment of choice for bipolar disorder?
136. Treatment of mania, mixed state, and rapid cycling
137. Anticonvulsants and antipsychotics in the treatment of bipolar disorder
138. The place of anticonvulsants and other putative mood stabilisers in the treatment of bipolar disorder
139. Antipsychotic drug side effect issues in bipolar manic patients
140. Atypical antipsychotics in the treatment of bipolar disorder: Pharmacological and clinical effects
141. The expert consensus guideline series: Medication treatment of bipolar disorder 2000
142. Clinical practice guidelines for bipolar disorder from the department of veterans affairs
143. Bodyweight gain with atypical antipsychotics: A comparative review